4:35 PM
 | 
Jun 02, 2010
 |  BC Extra  |  Company News

FDA extends Abstral review

FDA extended by three months the PDUFA date of June 4 for Abstral fentanyl from ProStrakan Group plc...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >